2017
DOI: 10.1016/j.eurpsy.2017.01.1625
|View full text |Cite
|
Sign up to set email alerts
|

Dopamine, glutamate and biotypes in the future of schizophrenia

Abstract: IntroductionApproximately a third of patients with schizophrenia show limited response to antipsychotic medication. As several studies have been suggesting new classifications to schizophrenia, our aim is to review different hypothesis and seek a new way of approaching patient's treatment in day-to-day practice.MethodsThe methods we used consisted on reviewing several papers that have recently been published on the area of classification and treatment of schizophrenia, considering an approach to the findings t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 0 publications
0
0
0
Order By: Relevance